On October 7, 2022 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported the Company’s participation in the following upcoming investor and industry conferences to be held in October 2022 (Press release, Genprex, OCT 7, 2022, View Source [SID1234621834]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: Dawson James Securities Annual Small Cap Growth Conference

Event: Immuno-Oncology Summit

Event: BIO Europe

Event: LD Micro Main Event XV

Live Webcast Link: https://bit.ly/3EgC5af

For those interested in meeting Genprex management at LD Micro’s Main event, please request a meeting through LD Micro or reach out to Kalyn Dabbs at [email protected].